Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis
Carmen Peña‐Bautista, Lourdes Álvarez‐Sánchez, Inés Ferrer, Marina López‐Nogueroles, Antonio José Cañada Martínez, Camille Oger, Jean‐Marie Galano, Thierry Durand, Miquel Baquero, Consuelo Cháfer‐Pericás
Abstract
BACKGROUND: Alzheimer disease (AD) is an increasingly common neurodegenerative disease, especially in countries with aging populations. Its diagnosis is complex and is usually carried out in advanced stages of the disease. In addition, lipids and oxidative stress have been related to AD since the earliest stages. A diagnosis in the initial or preclinical stages of the disease could help in a more effective action of the treatments. METHODS: = 31) by chromatography and mass spectrometry (UPLC-MS/MS). Participants were accurately classified according to cerebrospinal fluid (CSF) biomarkers and neuropsychological examination. RESULTS: Isoprostanoid levels did not show differences between groups. However, some of them correlated with CSF biomarkers (t-tau, p-tau) and with cognitive decline. In addition, a panel including 10 biomarkers showed an area under curve (AUC) of 0.96 (0.903-1) and a validation AUC of 0.90 in preclinical AD prediction. CONCLUSIONS: Plasma isoprostanoids could be useful biomarkers in preclinical diagnosis for AD. However, these results would require a further validation with an external cohort.